Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Auteurs : Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekjudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, Von Minckwitz G, Buyse M, Piccart-Gebhart M
Année : 2016
Journal : Ann Oncol
Volume : 27(6)
Pages : 1029-34